Welcome To RobinsPost.com


Related News Videos From Youtube For:

Pracinostat and Acute Myeloid Leukemia - Preliminary Data is Encouraging

Pracinostat is a histone deacetylase (HDAC) inhibitor being developed for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this exclusive interview with Rare Disease Report, Guillermo Garcia-Manero, MD of University of Texas MD Anderson Cancer Center talks about data his group presented at American Society of Hematology (ASH) annual meeting showing the combination of pracinostat plus azacitidine may improve outcomes in older patients with AML. Reference Garcia-Manero G, Atallah, E, Odenike O et al, Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML). Presented at” American Society Hematology Annual Meeting; December 6-9,2014; SanFrancisco CA. Abstract 947.

Why curing cancer is so hard | Azra Raza | TEDxNewYork

Acute Myeloid Leukemia -- Treatment

What is "MDS"? (Myelodysplastic Syndromes)

Acute myeloid leukemia (AML) - a life threatening cancer

Acute Myelogenous Leukemia (AML) Survivor: Danel Lawrence

Una Vision General de los Sindromes Mielodisplasicos

Terry Ikner- Diagnosed with AML APL Leukemia

Leukemia AML MDS Moon Shots update

Pracinostat and azacitidine for elderly AML

Myelodysplastic syndrome (MDS) survivor Holly Easley shares her thoughts on the Moon Shots Program